Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Talha Badar; Ahmad Nanaa; Ehab Atallah; Rory M. Shallis; Sacchi de Camargo Correia Guilherme; Aaron D. Goldberg; Antoine N. Saliba; Anand Patel; Jan P. Bewersdorf; Adam S. DuVall; Danielle Bradshaw; Yasmin Abaza; Guru Subramanian Guru Murthy; Neil Palmisiano; Amer M. Zeidan; Vamsi Kota; Mark R. Litzow

doi:10.1038/s41408-024-01000-2

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Talha Badar
, Ahmad Nanaa
, Ehab Atallah
, Rory M. Shallis
, Sacchi de Camargo Correia Guilherme
, Aaron D. Goldberg
, Antoine N. Saliba
, Anand Patel
, Jan P. Bewersdorf
, Adam S. DuVall
, Danielle Bradshaw
, Yasmin Abaza
, Guru Subramanian Guru Murthy
, Neil Palmisiano
, Amer M. Zeidan
, Vamsi Kota
, Mark R. Litzow

Pulmonary Disease

Research output: Contribution to journal › Letter › peer-review

28 Scopus citations

Abstract

(Figure presented.)

Original language	English (US)
Article number	32
Journal	Blood Cancer Journal
Volume	14
Issue number	1
DOIs	https://doi.org/10.1038/s41408-024-01000-2
State	Published - Dec 2024

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1038/s41408-024-01000-2

Fingerprint

Dive into the research topics of 'Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)'. Together they form a unique fingerprint.

Cite this

Badar, T., Nanaa, A., Atallah, E., Shallis, R. M., Guilherme, S. D. C. C., Goldberg, A. D., Saliba, A. N., Patel, A., Bewersdorf, J. P., DuVall, A. S., Bradshaw, D., Abaza, Y., Murthy, G. S. G., Palmisiano, N., Zeidan, A. M., Kota, V., & Litzow, M. R. (2024). Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood Cancer Journal, 14(1), Article 32. https://doi.org/10.1038/s41408-024-01000-2

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). / Badar, Talha; Nanaa, Ahmad; Atallah, Ehab et al.
In: Blood Cancer Journal, Vol. 14, No. 1, 32, 12.2024.

Research output: Contribution to journal › Letter › peer-review

Badar, T, Nanaa, A, Atallah, E, Shallis, RM, Guilherme, SDCC, Goldberg, AD, Saliba, AN, Patel, A, Bewersdorf, JP, DuVall, AS, Bradshaw, D, Abaza, Y, Murthy, GSG, Palmisiano, N, Zeidan, AM, Kota, V & Litzow, MR 2024, 'Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)', Blood Cancer Journal, vol. 14, no. 1, 32. https://doi.org/10.1038/s41408-024-01000-2

Badar T, Nanaa A, Atallah E, Shallis RM, Guilherme SDCC, Goldberg AD et al. Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood Cancer Journal. 2024 Dec;14(1):32. doi: 10.1038/s41408-024-01000-2

@article{40f3b10593eb4111854cc6052d85552d,

title = "Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)",

abstract = "(Figure presented.)",

author = "Talha Badar and Ahmad Nanaa and Ehab Atallah and Shallis, \{Rory M.\} and Guilherme, \{Sacchi de Camargo Correia\} and Goldberg, \{Aaron D.\} and Saliba, \{Antoine N.\} and Anand Patel and Bewersdorf, \{Jan P.\} and DuVall, \{Adam S.\} and Danielle Bradshaw and Yasmin Abaza and Murthy, \{Guru Subramanian Guru\} and Neil Palmisiano and Zeidan, \{Amer M.\} and Vamsi Kota and Litzow, \{Mark R.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = dec,

doi = "10.1038/s41408-024-01000-2",

language = "English (US)",

volume = "14",

journal = "Blood Cancer Journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia

T2 - results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

AU - Badar, Talha

AU - Nanaa, Ahmad

AU - Atallah, Ehab

AU - Shallis, Rory M.

AU - Guilherme, Sacchi de Camargo Correia

AU - Goldberg, Aaron D.

AU - Saliba, Antoine N.

AU - Patel, Anand

AU - Bewersdorf, Jan P.

AU - DuVall, Adam S.

AU - Bradshaw, Danielle

AU - Abaza, Yasmin

AU - Murthy, Guru Subramanian Guru

AU - Palmisiano, Neil

AU - Zeidan, Amer M.

AU - Kota, Vamsi

AU - Litzow, Mark R.

PY - 2024/12

Y1 - 2024/12

N2 - (Figure presented.)

AB - (Figure presented.)

UR - https://www.scopus.com/pages/publications/85185454442

UR - https://www.scopus.com/pages/publications/85185454442#tab=citedBy

U2 - 10.1038/s41408-024-01000-2

DO - 10.1038/s41408-024-01000-2

M3 - Letter

C2 - 38378617

AN - SCOPUS:85185454442

SN - 2044-5385

VL - 14

JO - Blood Cancer Journal

JF - Blood Cancer Journal

IS - 1

M1 - 32

ER -

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this